FGFR2 and gastric cancer: A number of other targeted therapeutics are currently being tested in mid to late stage GC trials including: AZD4547, targeting the FGFR2 gene [8, 9], and Onartuzumab [10], ARQ197 [11], AMG102 [12, 13] and crizotinib [14] all targeting the MET pathway [15].